Cargando…

Response of conventional chondrosarcoma to gemcitabine alone: a case report

Conventional skeletal chondrosarcoma is a bone neoplasm, which is poorly sensitive to anthracyclines-based chemotherapy. We report on an 18-month-long tumour response to gemcitabine as single agent in a young patient with an advanced secondary peripheral conventional chondrosarcoma, previously treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Provenzano, Salvatore, Hindi, Nadia, Morosi, Carlo, Ghilardi, Mara, Collini, Paola, Casali, Paolo G, Stacchiotti, Silvia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365557/ https://www.ncbi.nlm.nih.gov/pubmed/25793102 http://dx.doi.org/10.1186/s13569-015-0025-z

Ejemplares similares

Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib
por: Stacchiotti, Silvia, et al.
Publicado: (2012)

High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma
por: Colia, Vittoria, et al.
Publicado: (2017)

Solitary fibrous tumour presenting with a single bone metastasis: report of six cases and literature review
por: Colia, Vittoria, et al.
Publicado: (2016)

Extraskeletal Myxoid Chondrosarcoma: State of the Art and Current Research on Biology and Clinical Management
por: Stacchiotti, Silvia, et al.
Publicado: (2020)

Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review
por: Raimondi, Alessandra, et al.
Publicado: (2020)

Identification of an Actionable Mutation of KIT in a Case of Extraskeletal Myxoid Chondrosarcoma
por: Urbini, Milena, et al.
Publicado: (2018)

Anthracycline-based and gemcitabine-based chemotherapy in the adjuvant setting for stage I uterine leiomyosarcoma: a retrospective analysis at two reference centers
por: Fucà, Giovanni, et al.
Publicado: (2020)

Long‐term survivors with desmoplastic small round cell tumor (DSRCT): Results from a retrospective single‐institution case series analysis
por: Giani, Claudia, et al.
Publicado: (2023)

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2017)

Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid‐type fibromatosis
por: Zanchetta, Edoardo, et al.
Publicado: (2021)

Anthracycline-based chemotherapy in extraskeletal myxoid chondrosarcoma: a retrospective study
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature
por: Nasca, Vincenzo, et al.
Publicado: (2022)

Non-Conventional Treatments for Conventional Chondrosarcoma
por: Monga, Varun, et al.
Publicado: (2020)

Response to PD1 inhibition in conventional chondrosarcoma
por: Wagner, Michael J., et al.
Publicado: (2018)

NR4A3 fusion proteins trigger an axon guidance switch that marks the difference between EWSR1 and TAF15 translocated extraskeletal myxoid chondrosarcomas
por: Brenca, Monica, et al.
Publicado: (2019)

Response to isolated limb perfusion and chemotherapy with epirubicin plus ifosfamide in a metastatic malignant ossifying fibromyxoid tumor
por: Provenzano, Salvatore, et al.
Publicado: (2017)

Impact of Pathological Stratification on the Clinical Outcomes of Advanced Well-Differentiated/Dedifferentiated Liposarcoma Treated with Trabectedin
por: Fabbroni, Chiara, et al.
Publicado: (2021)

Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone
por: van Oosterwijk, Jolieke G, et al.
Publicado: (2012)

Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case report
por: Tazzari, Marcella, et al.
Publicado: (2015)

Survival and prognostic factors in conventional central chondrosarcoma
por: Fromm, Julian, et al.
Publicado: (2018)

Activity of anthracycline- and ifosfamide-based chemotherapy in a series of patients affected by advanced myxofibrosarcoma
por: Colia, Vittoria, et al.
Publicado: (2017)

Management of serious complications in intra‐abdominal desmoid‐type fibromatosis
por: Bini, Federica, et al.
Publicado: (2021)

Survival and prognostic factors in conventional G1 chondrosarcoma
por: Fromm, Julian, et al.
Publicado: (2019)

The Identification of Prognostic Factors and Survival Statistics of Conventional Central Chondrosarcoma
por: Nota, Sjoerd P. F. T., et al.
Publicado: (2015)

Gemcitabine plus cisplatin versus gemcitabine alone in the treatment of pancreatic cancer: a meta-analysis
por: Ouyang, Guoqing, et al.
Publicado: (2016)

Gemcitabine plus concurrent irreversible electroporation vs gemcitabine alone for locally advanced pancreatic cancer
por: Ma, Yang-Yang, et al.
Publicado: (2020)

Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib
por: Stacchiotti, Silvia, et al.
Publicado: (2013)

Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients
por: Baldi, Giacomo G, et al.
Publicado: (2013)

Expression profiling of microRNAs and isomiRs in conventional central chondrosarcoma
por: Parafioriti, Antonina, et al.
Publicado: (2020)

Prognostic Factors and Surgical Impact of Non‐metastatic Conventional Chondrosarcoma of the Extremities
por: Wang, Wenhui, et al.
Publicado: (2023)

Conventional chondrosarcoma with focal clear cell change: a clinicopathological and molecular analysis
por: Lam, Suk Wai, et al.
Publicado: (2019)

Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma
por: Dermawan, Josephine Kam Tai, et al.
Publicado: (2023)

Selenium Induces Pancreatic Cancer Cell Death Alone and in Combination with Gemcitabine
por: Wooten, David J., et al.
Publicado: (2022)

CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone
por: Wasan, H S, et al.
Publicado: (2009)

Performance status dynamics during treatment with nab-paclitaxel plus gemcitabine versus gemcitabine alone for metastatic pancreatic cancer
por: Chiorean, E Gabriela, et al.
Publicado: (2018)

Comparing the Efficacy and Safety of Gemcitabine plus Nab-Paclitaxel versus Gemcitabine Alone in Older Adults with Unresectable Pancreatic Cancer
por: Kobayashi, Satoshi, et al.
Publicado: (2022)

Does the Cambridge classification alone predict the possibility to perform echocardiographic examination in lateral recumbency in dogs affected by brachycephalic obstructive airways syndrome?
por: Bagardi, Mara, et al.
Publicado: (2023)

Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
por: Hagiwara, Yasuhiro, et al.
Publicado: (2017)

Prognostic predictive values of gemcitabine sensitivity-related gene products for unresectable or recurrent biliary tract cancer treated with gemcitabine alone
por: Murata, Akihiro, et al.
Publicado: (2013)

A Cost-Effectiveness Analysis of Gemcitabine plus Cisplatin Versus Gemcitabine Alone for Treatment of Advanced Biliary Tract Cancer in Japan
por: Tsukiyama, Ikuto, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_pa0p0srste8i5flo0bmetu0hu2